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Abstract
Polyomaviruses BK and JC are ubiquitous viruses with 
high seroprevalence rates in general population. Fol-
lowing primary infection, polyomaviruses BK and JC 
persist latently in different sites, particularly in the re-
no-urinary tract. Reactivation from latency may occur in 
normal subjects with asymptomatic viruria, while it can 
be associated to nephropathy (PVAN) in kidney trans-
plantat recipients. PVAN may occur in 1%-10% of renal 
transplant patients with loss of the transplanted organ 
in 30% up to 80% of the cases. Etiology of PVAN is 
mainly attributable to BK virus, although approximately 
5% of the cases may be due to JC. Pathogenesis of 
PVAN is still unknown, although viral replication and the 
lack of immune control play a major role. Immunosup-
pression represents the condicio sine qua non for the 
development of PVAN and the modulation of anti-rejec-
tion treatment represents the first line of intervention, 
given the lack of specific antiviral agents. At moment, 
an appropriate immunemodulation can only be accom-
plished by early identification of viral reactivacation by 
evaluation of polyomavirus load on serum and/or urine 
specimens, particularly in the first year post-trasplanta-
tion. Viro-immunological monitoring of specific cellular 
immune response could be useful to identify patients 
unable to recover cellular immunity posttransplanta-
tion, that are at higher risk of viral reactivation with 
development of PVAN. Herein, the main features of 
polyomaviruses BK and JC, biological properties, clinical 
characteristics, etiopathogenesis, monitoring and diag-
nosing of PVAN will be described and discussed, with 
an extended citation of related relevant literature data.
© 2012 Baishideng. All rights reserved.
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INTRODUCTION
Polyomavirus-associated nephropathy (PVAN) is one of  
the most common viral complications in renal transplant 
recipients and is an increasingly recognized cause of  re-
nal transplant dysfunction and graft loss. Since the first 
description of  PVAN in 1995, an increasing prevalence 
rate from 1% to 10% has been evidenced[1]. The increase 
in prevalence data could be due to the introduction of  
new deeply immunosuppressive drugs and/or the relative 
decline in acute rejection rates. PVAN can lead to kidney 
graft loss in 10% up to 100% of  the cases, determining 
the return in hemodialysis within 6 to 60 mo, thus signifi-
cantly and markedly reducing the graft survival. 
Viral replication is the single common feature of  all 
patients at risk of  nephropathy. Therefore, screening 
for viral replication is the most useful tool for the iden-
tification of  patients at risk of  developing nephropathy, 
thus allowing for earlier intervention, in particular a 
pre-emptive reduction of  immunosuppression, with im-
provement of  outcome. Beside virological monitoring, 
in recent years the role of  virus-specific cellular immune 
response in the control of  viral replication has prompted 
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the development and employment of  methods for viro-
immunological monitoring. 
The complexity regarding diagnosis, monitoring and 
clinical management of  PVAN evidences the need for a 
multidisciplinary approach, including nephrologists, pa-
thologists, and clinical virologists. 
HUMAN POLYOMAVIRUSES AND 
NEPHROPAHTY 
The most characterized polyomaviruses infecting humans 
and involved in the pathogenesis of  PVAN are BK virus 
(BKV) and JC virus (JCV), named after the initials of  the 
patients in which they were first isolated in 1971[2,3]. In re-
cent years, other polyomaviruses have been described in 
humans, including WU, KI, Merkel cell virus and others, 
however their clinical role is still undefined and no as-
sociation to nephropathy has been evidenced. Moreover, 
also the non-human primate polyomavirus SV-40 has 
been detected in human specimens and is associated to 
nephropathy in these primates in the presence of  immu-
nocompromised conditions, such as infection with simian 
immunodeficiency virus (Table 1). SV-40 was accidentally 
introduced as a pathogen into the human population as a 
contaminant of  early polio vaccines, both the inactivated 
one by Salk and the oral one by Sabin, between 1955 and 
1964[4]. Apart for polio vaccines, strong serological and 
molecular evidence suggests that new SV-40 infections 
may be occurring in the human population, although the 
route of  transmission remains unknown. Pathogenic role 
of  SV-40 in humans is controversial and recent studies 
evidenced the risk of  false positive results because of  
contamination by common laboratory plasmids contain-
ing SV-40 sequences[5-7]. Nevertheless, like other poly-
omaviruses, SV-40 displays renotropism and is believed 
to latently persist in the kidney after primary infection. 
Polyomaviruses BK and JC are ubiquitous, with sero-
prevalence rates ranging from 70% to 90% in adult popu-
lation. Primary infection usually occurs early in the child-
hood, at a median age of  5 years, and is characterized by 
low upper respiratory tract morbidity or is asymptomatic. 
Following primary infection, BKV and JCV remain latent 
in different sites, including the renourinary tract, as the 
epidemiologically most relevant latency site, B cells, brain, 
spleen, and probably other organs. Periodical reactivation 
may occur in both immunocompetent individuals (in 0% 
up to 62%) and immunocompromised patients[8] and is 
evidenced by asymptomatic viruria. 
In contrast to BKV, that is found infrequently in the 
urine of  healthy adults, JC viruria occurs universally, 
increasing with age. In a study on 400 healthy blood do-
nors, Egli and colleagues evidenced that JC viruria was 
significantly more frequent and at a higher viral load in 
comparison to BK viruria (19% vs 7%, P < 0.0001)[9]. 
According to the Authors, these data indicate significant 
differences between BKV- and JCV-infected cells with re-
spect to anatomic location and/or accessibility to T cells 
in mucosal sites. 
At the time of  first description of  BK in 1971, the 
pathogenic role of  BKV remained elusive and it has been 
considered an orphan virus for many years afterwards. 
In 1978, Mackenzie and colleagues first described four 
features of  nephropathy in renal transplantation: (1) the 
detection of  urinary decoy cells; (2) the presence of  viral 
inclusions in uroepithelial cells in graft biopsies; (3) the 
difficulties in the differential diagnosis with acute rejec-
tion; and (4) the role of  immunosuppression in the devel-
opment of  these findings[10]. 
In 1995, Purighalla and colleagues described the first 
case of  PVAN and recognized it as a defined disease 
entity[11]. Subsequently, several reports with increasing 
prevalence rates from many transplant centres worldwide 
followed, evidencing a stepwise increase in incidence of  
PVAN from approximately 1% in 1995 to 5% or even 
more in 2001. Subsequently, studies from 2002 to 2004 
reported PVAN with prevalence rates of  1% to 10% 
(mean 5.1%). The majority of  the cases occur in the first 
year posttransplantation, although approximately 25% 
of  cases are diagnosed later. Clinical impact is relevant, 
as loss of  the renal graft ranges from 30% up to > 80% 
of  cases[12-14]; in transplant centres where screening for 
polyomavirus replication in the urine and plasma is per-
formed, the rate of  graft loss is lower[15]. 
Several studies evidenced that BK viremia is only 
rarely observed in non-kidney solid organ transplant 
recipients and biopsy-confirmed cases of  nephropathy 
have been described in few case reports[16-22], despite the 
similar or even higher level of  immunosuppression, thus 
supporting the role of  organ determinants in the patho-
genesis of  PVAN.
In hematopoietic stem cell transplant recipients, poly-
omavirus BK replication is commonly associated to hem-
orrhagic cystitis. Its incidence in this population ranges 
from 5.7% to 7.7%[23,24]. A case of  polyomavirus-induced 
hemorrhagic cystitis in renal transplantation patient with 
polyomavirus nephropathy has been reported[25]. 
Polyomavirus JC was first isolated in brain tissue from 
a patient with progressive multifocal leukoencephalopa-
thy, a demyelinating disease caused by lytic replication of  
the virus in oligodendrocytes and observed in the setting 
of  profound cellular immunosuppression, such as ac-
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Table 1  Polyomaviruses detected in humans and involved in 
the pathogenesis of polyomavirus-associated nephropathy
Virus Host Clinical diseases
BKV Human PVAN in renal transplantation
Hemorrhagic cystitis in bone 
marrow transplantation
JCV Human Progressive multifocal 
leukoencephalopathy
PVAN in renal transplantation
SV-40 Non-human primate Unknown; PVAN in renal 
transplantation?
PVAN: Polyomavirus-associated nephropathy; BKV: BK virus; JCV: JC 
virus.
quired immunodeficiency-syndrome. JCV has been also 
associated to nephropathy in kidney transplant recipients.
In fact, the etiological agent of  PVAN is BKV in 
most of  the cases, while JCV has been recognized as 
the etiologic agent in less than 3% of  all reported cases, 
alone[26,27] or in association to BKV[28]. Nevertheless, it is 
likely that the role of  JCV is more relevant than that re-
ported. In a recent study[29], a biopsy-proven PVAN was 
diagnosed in six kidney graft recipients with exclusive 
JCV viruria out of  75 patients (8%) with BKV and/or 
JCV viruria, thus accounting for an overall incidence dur-
ing the study period of  0.9%. 
A potential role for SV-40 in the etiology of  PVAN 
has been also suggested. Butel and colleagues[30] found 
that SV-40 seropositivity in children increased with age 
and was significantly associated to kidney transplantation. 
A co-infection with BKV and SV-40 has been described 
in two of  six renal transplant patients with PVAN[31].
The pathogenesis of  PVAN is still only incompletely 
understood, although it is now recognized that the inter-
action of  multiple factors concurs to the development of  
PVAN, including patient, organ, and viral determinants. 
In all the cases, the condicio sine qua non for the develop-
ment of  PVAN is the presence of  intense immunosup-
pression. Nephropathy has been associated particularly, 
but not exclusively, to triple immunosuppressive therapy, 
including tacrolimus, mycophenolate mofetil, and ste-
roids. It has been noted that the emergence of  PVAN 
coincided with the diffuse use of  tacrolimus and myco-
phenolate mofetil, although there is no proved causal re-
lationship, due to the different mechanisms of  action of  
these drugs[1,32]. It seems that the overall level of  immu-
nosuppression rather than a specific agent is involved in 
the pathogenesis of  PVAN, although we cannot exclude 
a drug-specific mechanism. The importance of  immuno-
suppression is also underlined by the fact that the main 
line of  intervention is by modulating immunosuppres-
sion, in particular reducing, switching or discontinuing a 
specific immunosuppressive agent. 
The preferential manifestation in renal allograft as 
compared to the native kidney of  other solid-organ trans-
plant recipients, suggests the role of  other factors. 
Among patient-related determinants, the following 
determinants have been identified as possibly contribut-
ing to PVAN: age > 50 years, male gender, white ethnic-
ity, pre-transplantation BKV seronegativity in children, 
interferon (IFN)-γ producing specific T-cells, presence of  
comorbidities such as diabetes mellitus and cytomegalo-
virus coinfection. 
Among organ determinants, the following factors 
have been considered as associated to viral replication 
and PVAN: HLA mismatching, previous episodes of  
acute rejection (treated with anti-lymphocyte preparations 
and intravenous steroid boluses), viral load in the renouri-
nary tract, presence of  renal injury (including calcineurin-
inhibitor toxicity, in fact the reduction of  this class of  
drug represents the very first line of  intervention). 
Among viral determinants, BKV genotypes (mutations 
in domain of  VP1 gene) and rearrangements in NCCR 
with presumably increased viral fitness. 
Determinants involved in determining the risk of  
PVAN are summarized in Table 2.
CLINICAL AND HISTOLOGIC FEATURES 
PVAN is typically diagnosed within the first year post-
transplantation, although approximately 25% of  the cases 
are seen later (range, 1.3-45.1 mo). Clinical presentation 
may be inconspicuous and lacks of  useful features. Vary-
ing degrees of  renal dysfunction may be seen, although 
in early stages even normal serum creatinine levels may 
be detected. PVAN may consist in interstitial nephritis 
and/or ureteric stenosis with ureteric obstruction, hydro-
nephrosis, and sometimes associated urinary tract infec-
tions. Progressive renal failure is reported in approxi-
mately 30%-60% of  the cases[33].
The stereotypical evolution of  PVAN has been thor-
oughly characterized and is as follows[34]. Most of  the cas-
es are preceded by an asymptomatic phase of  persistent 
and significant viruria, as demonstrated by the evidence 
of  a urine viral load > 105 copies/mL by polymerase 
chain reaction or by urine cytology (urinary decoy cells for 
at least 2 mo). Sustained BK viruria is typically followed 
within few weeks by viremia. A significant and sustained 
viremia (identified as > 5000 copies/mL plasma for 3 
consecutive weeks) identifies patients with uncontrolled 
viral replication potentially leading to parenchymal injury. 
Progression of  PVAN leads to eventual deterioration of  
the kidney graft function. Usually, appearance of  viruria 
and viremia precedes the increase in serum creatinine 
by weeks or months. Options for clinical interventions 
vary in relation to the stage of  PVAN course. In patients 
with viremia and viruria, a patient’s tailored reduction of  
immunosuppression before a significant renal injury has 
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Table 2  Determinants in the development of polyomavirus-
associated nephropathy
Determinants
Patient-related Age > 50 yr
Male gender
Comorbidities (diabetes mellitus)
Negative serostatus before transplantation







Immunity-related Intense triple immunosuppression (calcineurin-
inhibitor, antiproliferative agent, steroid)
Rejection and anti-rejection treatment (anti-
lymphocyte preparations, iv steroid boluses)
Positive serostatus of donor
Low number of BKV-specific T-cells
NCCR: Noncoding control region; BKV: BK virus.
Costa C et al . PVAN
occurred leads to the resolution of  the infection in up to 
90% of  the cases with long term preservation of  renal 
function and a low risk of  acute rejection (10%-15%). No 
intervention is required in the sole presence of  viruria. In 
the presence of  viruria and viremia, increased serum cre-
atinine level and renal injury at graft biopsy, the interven-
tion by reducing immunosuppression is mandatory. Late 
diagnosis and intervention, once that graft dysfunction 
is evident, decreases significantly the likelihood of  viral 
clearance and is associated with higher probability of  graft 
loss (30% vs < 10%). In patients with end-stage PVAN, 
intervention is usually late and ineffectual; the end-stage 
PVAN is clinically and histologically similar to end-stage 
renal disease with progressive obliteration of  the renal 
tubules and decrease in viremia and viruria. 
PVAN displays a (multi)focal distribution in the kidney. 
Histologic diagnosis of  PVAN is based on the detection 
of  typical basophilic nuclear viral inclusion in epithelial 
cells (renal tubular and/or Bowman’s capsular lining uro-
thelium). The virus is identified by immunohistochemical 
staining for the so-called SV40 Large T antigen, which 
cross-reacts with polyomaviruses BKV, JCV, and SV40. 
Histologic patterns of  PVAN are based on the identifica-
tion and extend of  inflammatory infiltrates and fibrosis 
in association with viral infection[34]. The following pat-
terns have been described: pattern A with viral cytopathic 
changes within a normal renal parenchyma, scant or no 
tubular atrophy, interstitial fibrosis and inflammation; 
pattern B with combination of  viral cytopathic changes 
and focal/multifocal areas of  tubular atrophy/interstitial 
fibrosis/inflammation (< 25% for pattern B1; 25%-50% 
for pattern B2; > 50% for pattern B3); pattern C (end-stage 
PVAN) with scarce viral cytopatic changes within a dif-
fusely scarred renal tissue and extensive tubular atrophy/
interstitial fibrosis/inflammation.
DIAGNOSIS 
The definitive diagnosis of  PVAN is made by histopatho-
logic evaluation, however this presents some drawbacks, 
including limited sensitivity due to focal involvement, thus 
accounting for sampling errors; varying presentations 
with cytopatic-inflammatory and/or fibrotic/scarring pat-
terns; difficult differential diagnosis from acute rejection, 
that may coexist with a opposite impact on intervention 
strategies. As the main line of  intervention is by reducing 
immunosuppression, early diagnosis is fundamental for 
a pre-emptive treatment, before the instauration of  renal 
injury. Considering the main pathogenic factors of  PVAN, 
i.e., viral replication and failure of  immune surveillance, 
earl diagnosis may be accomplished by virological and 
viro-immunological monitoring, consisting in monitoring 
of  viral replication and evaluation of  virus-specific im-
mune response, respectively.
VIROLOGICAL MONITORING
Viral replication is the single common feature of  all renal 
transplant recipients at risk of  PVAN. Therefore, screen-
ing for viral replication allows for the identification of  
patients at risk of  developing PVAN, thus permitting 
earlier intervention consisting in a pre-emptive reduction 
of  immunosuppression[35], with improvement of  the out-
come. Screening for viral replication presents a high pre-
dictive value (100%), as in the absence of  viral replication, 
PVAN is excluded[36]. Moreover, virological monitoring 
is the most important tool for evaluating the response to 
the treatment in patients with confirmed PVAN. Differ-
ent screening assays are available and include: (1) urine 
cytology, i.e., the detection of  decoy cells that are pres-
ent in 40% to 60% of  transplant recipients, although it 
represents a good screening test with a 100% negative 
predictive value, positive predictive value is very low (ap-
proximately 20%)[33]; (2) quantification of  urinary BKV-
DNA, with a load 100-fold higher than plasma viral load 
that is found in 30% to 40% of  transplant recipients, with 
a positive predictive value of  approximately 40%[33]; and 
(3) quantification of  plasma BKV-DNA, with a viral load 
higher than 104 copies/mL recommended for a presumed 
diagnosis of  PVAN[32,37,38]; quantification of  urinary VP1 
mRNA that is likely to mirror active viral replication. 
Different screening methods present some drawbacks, 
for example urine cytology and urinary VP1 mRNA 
measurement are susceptible to preanalytic hazards due 
to the type and duration of  processing, viruria may dif-
fer depending on the type of  specimen (supernatant, cell 
pellet, resuspended urine), micturition intervals and fluc-
tuations of  urine content, inhibition of  polymerase chain 
reaction in urine (e.g., depending on urea concentration) 
for viruria. 
As regards VP1 mRNA, this assay was first proposed 
as a tool for noninvasive diagnosis of  PVAN adopting a 
cut-off  of  6.5 × 105 copies/nanogram of  total RNA[39] 
and has been recently described as a complementary assay 
to investigate viral replication on the basis of  the results 
of  a study having found that the mean copy number in 
patients without PVAN was significantly lower than that 
in biopsy-proven nephropathy[40], and the assay has been 
validated in an independent cohort of  renal transplant pa-
tients[41]. However, the use of  VP1 mRNA measurement 
has been criticized as it is dependent on the purity of  the 
RNA preparation and contamination by the encoding 
viral genomic VP1 DNA contaminating the VP1 cDNA 
preparation has been indicated as being potential respon-
sible for falsely high results[42]. We have recently evaluated 
the role of  urine VP1 mRNA quantification in a large 
cohort of  kidney transplant recipients and found that, by 
analyzing the operating characteristics, VP1 messenger 
study was not superior to viremia and was otherwise lim-
ited by the technical complexity in comparison to DNA 
detection[43]. 
According to the Consensus Recommendations of  a 
panel of  international experts, screening for polyomavi-
rus replication should be made by urine cytology or urine 
DNA load evaluation; recommended screening intervals 
are as follows: every 3 mo up to 2 years posttranplantation 
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or when allograft dysfunction occurs or when allograft 
biopsy is performed. In the presence of  a positive screen-
ing tests (possible PVAN), adjunctive quantitative assays 
with identification of  cut-off  levels are recommended, 
including a urine DNA load > 107 copies/mL or plasma 
DNA load > 104 copies/mL. In the presence of  a positive 
adjunctive test above the threshold (presumptive PVAN), 
allograft biopsy is recommended in order to make a de-
finitive diagnosis of  PVAN and prompt intervention. 
Response to the treatment is monitored every 2-4 wk by 
evidencing a reduction of  urine and plasma DNA load 
until resolution of  PVAN. 
The performance characteristics of  tests for screening 
of  polyomavirus replication have been evaluated in recent 
studies. Based on a study by Viscount and colleagues[44] 
on a cohort of  114 kidney transplant recipients with four 
cases of  confirmed PVAN, BKV-PCR may prove supe-
rior to urine cytology, particularly in terms of  sensitivity 
and positive predictive value. A plasma DNA load > 1.6 
× 104 copies/mL evidenced an improved specificity to 
96% (vs 91% for plasma load of  104 copies/mL, 92% for 
urine load > 2 × 107 copies/mL, and 84% for urine cy-
tology) without reducing sensitivity (100% for all the mo-
lecular assays, as all the PVAN cases presented this viral 
load, vs 25% for urine cytology), however positive predic-
tive value was only 50% (vs 29% for plasma load of  104 
copies/mL, 312% for urine load > 2 × 107 copies/mL, 
and 5% for urine cytology). Nevertheless, the important 
clinical value of  a negative polymerase chain reaction test 
is well established. In a similar study performed at the 
Renal Transplant Centre of  Turin, Italy, on 229 patients 
with three cases of  confirmed PVAN (accounting for an 
overall prevalence of  1.3%), a viremia level > 1.6 × 104 
copies/mL was found in four cases, three of  which with 
PVAN. The following operating characteristics for the 
diagnosis of  PVAN were achieved: sensitivity 100%, spe-
cificity 99.6%, positive predictive value 75%, and negative 
predictive value 100%; of  course, the low number of  
PVAN cases represents a limitation of  this study[15].
Virological monitoring for PVAN at the Renal Trans-
plant Centre of  Turin, Italy, includes screening of  viruria 
and viremia twice monthly in the first 3 mo posttransplan-
tation, thereafter every 3 mo during the first 2 years and 
then yearly until the 5th year. Due to the possibility of  
self-limiting (transient) replication, positive screening as-
says are confirmed within 2-4 wk. 
Renal biopsy is performed in case of  suspected re-
jection, PVAN or declining renal function; in fact, also 
considering the potential for sampling errors due to 
focal involvement, renal biopsy is necessary to exclude 
other pathologic processes, such as acute rejection that 
may coexist[45]. At our centre, considering that in early 
stages of  PVAN viral inclusions may be absent, as well 
as inflammation may be scarce[46], beside histopathologic 
evaluation, also quantification of  polyomavirus DNA 
on renal graft biopsies and/or ureteric specimens is per-
formed. Polyomavirus-DNA quantitation could be useful 
in the presence of  little evidence of  viral cytopathy[46]. In 
a study on quantitation of  polyomaviruses BK and JC 
in human kidneys, the highest tissue viral loads (e.g., > 
103 copies/cell) were found in active PVAN, while it was 
significantly lower in pre-PVAN biopsies and in speci-
mens from patients with asymptomatic viruria[47]. Similar 
results were obtained by our group in a study on 109 
renal transplant patients with two cases of  histologically 
confirmed PVAN, with tissue BKV load > 104 copies/
cell in both PVAN cases and < 102 copies/cell in patients 
with asymptomatic viruria or pre-PVAN[48]. Overall, these 
studies evidenced that viral load are significantly higher 
in active PVAN and underline the low sensitivity of  tis-
sue polymerase chain reaction in early stages of  infection, 
possibly reflecting the low sensitivity due to focal involve-
ment, as already described for histopathology.
Recommended algorithm for virological monitoring 
of  polyomavirus BK replication in renal transplant recipi-
ents[49] is summarized in Table 3.
VIRO-IMMUNOLOGICAL MONITORING
Among determinants potentially involved in the patho-
genesis of  PVAN, there are immunity-related risk fac-
tors. These include immunosuppressive therapy, use of  
steroids, HLA-mismatching, rejection and anti-rejection 
treatment, and factors related to polyomavirus-specific 
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Table 3  Algorythm for the virological monitoring of polyomavirus BK replication in renal transplantation[49]
Assay Notes Timing - intervention
Screening Positive screening test (possible PVAN) Every 3 mo up to 2 yr post-transplantation or in case of 
allograft dysfunction or when renal biopsy is performed   Urine cytology (decoy cells) or urine DNA load
Adjunctive quantitative tests (threshold) Presumptive PVAN Pre-emptive reduction of immunosuppression
   Urine DNA load > 107 copies/mL or plasma 
   DNA load > 104 copies/mL
Allograft biopsy Definitive diagnosis of PVAN
Monitoring of response to treatment Every 2-4 wk
   Urine DNA load decreasing or plasma DNA 
   load decreasing
   Serum creatinine
Negative monitoring test (resolved PVAN)
PVAN: Polyomavirus-associated nephropathy.
Costa C et al . PVAN
immune response[50]. Both humoral and cellular response 
may be associated to BKV replication and PVAN.
As regards humoral response to BKV and PVAN risk, 
it has been evidenced that BKV-seropositive recipients 
are not protected from viral replication and PVAN[12]. 
For example, in a study on 78 renal transplant patients, 
PVAN occurred in four of  the 59 (76% of  the whole 
study population) seropositive individuals and in one 
of  the 19 (24%) seronegative patients[12]. On the other 
hand, BKV-seronegative recipients are at higher risk of  
viral replication and nephropathy[51-53]. For example, BK 
viruria was significantly more frequent in seronegative 
recipients in comparison to seropositive patients (58% vs 
21% in a study population of  24 and 56 pediatric kidney 
transplant patients, respectively; P < 0.005)[51]. Never-
theless, although specific antibodies may accelerate the 
clearance of  primary infection, they seem to play only a 
minimal role in the containment of  PVAN. In fact, al-
though a significant increase in immunoglobulins G titer 
is seen in patients with decreasing viremia values and af-
ter the resolution of  PVAN[52-54], individuals with elevated 
immunoglobulins G levels can still develop PVAN, thus 
suggesting a role of  defective cellular immune response 
in the onset of  nephropathy[55]. 
Until recently, studies on immune response to BKV 
have been limited, due to the little pathologic potential 
in immunocompetent individuals. It has been evidence 
that BK-seropositive healthy subjects present CD4+ 
and CD8+ cells specific for BKV Large T antigen and 
the capsid protein VP1; in particular, CD4+ T cells with 
cytotoxic potential seem to play a role in maintaining 
memory responses to BKV and contribute to the im-
mune control of  viral replication[56]. 
In renal transplant patients, it has been evidenced that 
control of  BKV replication and PVAN is correlated with 
the development or reconstitution of  BKV-specific cellu-
lar immune response; whereas the lack of  a protective im-
munity may favour the occurrence of  active infection and 
progression to PVAN[54,57]. The fundamental role of  T-cell 
immune response in the control of  BKV replication was 
first observed by the indirect evidence of  increased inci-
dence of  viral reactivation and development of  disease in 
relation to the degree of  immune compromise[8,32,49,58]. 
Evaluation of  BKV-specific cellular immune response 
could be accomplished by lymphocyte stimulation with 
inactivated cultured virus or specific epitopes/overlap-
ping peptide pools derived from VP1 and Large T anti-
gens (i.e., virus-specific stimulation step) and detection 
of  cellular immunity by labelled major histocompatibility 
complex class I tetramers, by intracellular staining and 
flow cytometry analysis, or by the enzyme-linked immu-
nosorbent spot (ELISPOT) assay for IFN-γ. 
By using one of  these assays, several studies have 
evidenced that kidney transplant recipients with with 
BK viremia or nephropathy failed to mount or expand a 
virus-specific cellular immune response, in comparison 
to seropositive healthy individuals or renal transplant 
patients with no evidence of  infection (negativity of  
viruria and viremia) or with evidence of  infection in the 
presence of  good renal function (evidence of  viruria, 
but no increase in serum creatinine)[54]. In particular, in 
patients with PVAN, no IFN-γ-secreting cell was detect-
able; whereas, in patients with PVAN, after reduction of  
immunosuppression, an increase in the number of  IFN-
γ-secreting cells to levels similar to those of  healthy sub-
jects was evidenced, in concomitance with a reduction of  
viremia and viruria. In seronegative healthy individuals no 
cellular immunity is detectable[54]. 
A defined association between viremia dynamics and 
BKV-specific cellular immunity has been evidenced. In 
a study on renal transplant recipients, cellular response 
to both Large T antigen and VP1 resulted significantly 
lower in patients with increasing or persistent viral load 
(n = 22 patients) in comparison to those with decreas-
ing (al least 2 log10 copies/mL) viral load or past PVAN 
(n = 20 patients)[57]. An example of  the course of  BK 
viral load and virus-specific cellular immune response in 
a kidney transplant recipient with polyomavirus reactiva-
tion treated with pre-emptive reduction of  maintenance 
immunosuppression has been reported by Comoli and 
colleagues[55]: the emergence of  BKV-specific T-cells co-
incides with the reduction of  viral load; the concomitant 
reduction of  serum creatinine indicates stabilization of  
graft function. This last finding seems to argue against 
the hypothesis that mounting of  cellular immunity is a 
major determinant of  tissue damage, as previously pro-
posed for hemorrhagic cystitis in bone marrow trans-
plantation[54,57,59]. Nevertheless, an inflammatory reaction 
mediated by different effectors may contribute to graft 
damage in case of  prolonged viral cytopathic damage[60,61]. 
Overall, these observations represent the basis by which 
it seems reasonable to manage therapeutic modulation by 
complementing quantification of  viral load (virological 
monitoring) with measurement of  specific cellular immu-
nity (viro-immunological monitoring). 
Prolonged and deep immunosuppression is consid-
ered as the most important determinant in the develop-
ment of  PVAN. In particular, although viral replication 
and PVAN has been associated to the overall level of  
immunosuppression rather than a specific drug, triple 
therapy including tacrolimus, mycophenolate mofetil and 
prednisone[62-64] seems to be associated with a higher risk 
than cyclosporine. The mechanism of  action of  anti-
rejection drugs interferes with the T cell activity. Calci-
neurin inhibitors (i.e., cyclosporine and tacrolimus) inter-
fere with T cell activation (signal-1); whereas mammalian 
target of  rapamycin (mTOR) inhibitors (i.e., sirolimus 
and everolimus) and anti-proliferative agents (i.e., azathio-
prine and mycophenolate mofetil) interfere with T cell 
proliferation downstream of  the interleukin-2-receptor 
activation (signal-3)[35,63,65]. 
Tacrolimus trogh levels > 8 ng/mL, and higher doses 
of  tacrolimus or mycophenolate mofetil, have been asso-
ciated to polyomavirus replication and the development 
of  PVAN[66]. Conversely, the reduction of  tacrolimus 
trough levels to 6 ng/mL and of  the daily dose of  myco-
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phenolate mofetil to ≤ 1 g, determined an improvement 
or stabilization of  PVAN in most of  the cases[67]. Accord-
ing to current consensus recommendations[49], tacrolimus 
trough levels should be targeted to 6 ng/mL, cyclospo-
rine A to 100-150 ng/mL, and mycophenolate mofetil 
should be reduced to a daily dose ≤ 1 g or discontinued.
As no effective antiviral therapy is available, the mile-
stone of  treatment is represented by the pre-emptive re-
duction of  immunosuppression on the basis of  virologi-
cal monitoring, although no protocol has been defined. 
Based on the knowledge of  the mechanisms of  action, 
it can be hypothesized that the frequency of  BKV-specific 
IFN-γ producing T cells is impacted by the immunosup-
pressive treatment. A recent study, using IFN-γ ELISPOT 
assays, investigated immunosuppressive drug levels and 
BKV Large T antigen-specific T cell responses in kidney 
transplant recipients in vivo and in healthy donors after 
titrating immunosuppression in vitro[68]. Based on their re-
sults, in kidney transplant patients in vivo (n = 16), respons-
es resulted inversely correlated with tacrolimus trough 
levels (P < 0.002), but not with mycophenolate mofetil, 
prednisone or the overall immunosuppressive dosing. 
In vitro tacrolimus concentrations > 6 ng/mL resulyed in 
inhibition of  BKV-specific T cell responses more than 
50%, while inhibition was less than 30% with tacrolimus 
concentration < 3 ng/mL. Cyclosporine A resulted in 
> 50% inhibition of  BKV-specific cellular responses at 
concentrations of  1920 ng/mL and less than 30% at con-
centrations below 960 ng/mL (corresponding to clinical 
C0 trough levels of  200 and 100 ng/nL, respectively). No 
inhibition of  BKV-specific T cell responses was observed 
for mycophenolate mofetil levels up to 8 µg/mL, lefluno-
mide 50 g/mL, or sirolimus concentrations of  64 ng/mL. 
Overall, the results obtained by Egli and colleagues[68] sug-
gested that calcinuerin-inhibitor concentrations are crucial 
for the development and/or recovery of  BKV-specific T 
cell responses. Therefore, reduction of  calcineurin inhibi-
tors should be considered as the first line of  intervention 
in the presence of  a presumptive diagnosis of  PVAN, 
whereas switching to mTOR inhibitors may represent an 
alternative or the second line of  intervention. These data 
should be confirmed in clinical trials.
TREATMENT
There is no approved and defined treatment for PVAN. 
The main line of  intervention is by reducing immmu-
nosuppression. Antiviral agents have been used, but no 
defined treatment is recommended and results are con-
teoversial. More recently, the use of  the immunomodu-
lant agent leflunomide, together with the reduction of  
immunosuppression has been proposed.
As the majority of  cases of  PVAN have been associ-
ated to triple immunosuppressive therapy including com-
binations of  calcineurin inhibitors (tacrolimus, cyclospo-
rine A), antiproliferative agents (mycophenolate mofetil, 
azathioprine) and corticosteroids, most of  recommended 
strategies includes decreasing, switching or stopping the 
ongoing treatment.
Immunosuppressive reduction
The recommended treatment of  PVAN by modification 
of  maintenance immunosuppression is summarized in 
Table 4[49]. Discontinuation of  mycophenolate mofetil or 
azathioprine and reduction of  immunosuppression by 
25%-50% were commonly used strategies[69]. Graft failure 
after immunosuppression reduction alone can be ob-
served in approximately 8% of  the patients[69]. Following 
reduction of  immunosuppression, biopsy-proven acute 
rejection has been observed in approximately 25% of  
patients[49]. These episodes of  rejection may be treated by 
steroid without recurrence of  PVAN[12,63]. 
Acute rejection and PVAN may coexist. In cases of  
concurrent biopsy-confirmed acute rejection and PVAN, 
a two-step approach of  anti-rejection treatment followed 
by the reduction of  immunosuppressive treatment has 
been adopted by several studies, that obtained the stabili-
zation or improvement of  allograft function[12,31,70,71]. 
The response to the immunosuppression reduction 
should be monitored by viruria and viremia evaluation 
every 2-4 wk[49]. Some studies evidenced clearance of  
viruria and viremia in most of  the patients, with clearance 
rates ranging from 7% to 80% for viruria and from 40% 
to 96% for viremia. However, based on creatininemia 
evaluation, renal function did not always improve with 
the reduction of  immunosuppression[72-74].
Immunosuppression reduction with antivirals
Antiviral agents, in particular cidofovir, have been investi-
gated in addition to the reduction of  immunosuppression 
for the management of  PVAN. However, results evi-
denced a scarce, if  any, significant effect in clearing viru-
ria or viremia[75-78]. Other studies reported clearance of  
viremia in 50% to 100% of  the cases[75,79-82]. The effect of  
cidofovir on renal function was variable, with some stud-
ies evidencing stabilization of  creatinine[79-81] and others 
Table 4  Recommended treatment of polyomavirus-associated nephropathy by reduction or switching of 
immunosuppression[49]
Switching Decreasing
Tacrolimus → Cyclosporine A (trough levels 100-150 ng/mL) Tacrolimus (trough levels < 6 ng/mL)
Mycophenolate mofetil → Azathioprine (dose ≤ 100 mg/d) Cyclosporine A (trough levels 100-150 ng/mL)
Tacrolimus → sirolimus (trough levels < 6 ng/mL) Mycophenolate mofetil dose ≤ 1 g/d
Mycophenolate mofetil → sirolimus (trough levels < 6 ng/mL) Cyclosporine A (trough levels 100-150 ng/mL)
Mycophenolate mofetil → leflunomide 
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showed no effect on renal function[75,77]. The pronounced 
nephrotoxicity limits the use of  cidofovir particularly 
in renal transplantation and an adequate hydratation is 
required. Vidarabine is used in the treatment of  BKV-
associated cystitis in bone marrow transplant recipients; 
its efficacy in nephritis is unknown[33]. 
Immunosuppression reduction with leflunomide
More recently, the use of  the immunomodulant agent 
leflunomide has been proposed for the treatment of  
patients with PVAN, in addition to the reduction of  im-
munosuppression. Leflunomide is an immunosuppressive 
agent, however its metabolite A77 1726 exhibits antiviral 
activity in vitro. Among the few studies that have evaluated 
the role of  leflunomide in treating PVAN, three reported 
results of  viral clearance with treatment[83-85] with signifi-
cant decreases in viremia and viruria with leflunomide 
alone or leflunomide plus cidofovir. Moreover, treatment 
with leflunomide stabilized or improved renal function in 
most of  the cases. 
Other interventions and retransplantation 
Among drugs having evidenced a polyomavirus-inhibito-
ry activity in vitro, beside cidofovir and leflunomide, there 
are certain quinolone antibiotics. Based on the results of  
a recent study, a 1-mo fluroquinolone course after trans-
plantation is associated with significantly lower rates of  
BK viremia at 1 year in comparison to patients with no 
fluoroquinolone, therefore suggesting the usefulness of  
these antibiotics at preventing viremia in kidney graft re-
cipients[86]. However, these results should be further con-
firmed by other studies, given the lack of  clinical trials. 
Amantadine has been used in the treatment of  PVAN 
with poor effect[33]. γ globulin has been used in order to 
augment the immune response, however the real efficacy 
is unknown[33]. 
Consideration of  retransplantation in the context of  
PVAN has become an increasingly relevant issue, with 
some unsolved questions regarding timing of  retrans-
plantation, i.e., preemptive vs after progression to renal 
failure. There is only limited experience about this in 
patients who have lost a previous graft due to PVAN. 
Retransplantation has been reported in a total of  21 
cases[87-90], four of  which were performed pre-emptively. 
All preemptive cases were performed with concomitant 
graft nephrectomy because of  the risk of  possible rein-
fection. Nevertheless, Cooper and colleagues[90] reported 
for the first time a successful preemptive retransplanta-
tion for PVAN in a patient without simultaneous graft 
nephrectomy. This cases evidenced that retransplantation 
could be pursued without nephrectomy for patients with 
PVAN provided the absence of  viral replication and an 
active surveillance protocol. The need for close monitor-
ing of  viral replication both in the immediate posttrans-
plantation setting (to minimize the risk of  development 
of  PVAN) and in the context of  graft failure (to indicate 
proper management and retransplant option) remains 
critical. 
CONCLUSION
In the past decade, PVAN has emerged as one of  the 
most relevant viral diseases occurring in renal transplan-
tation. Its increasing incidence has underlined the role 
played by immunosuppression in its pathogenesis. The 
major determining factors are now recognized as the oc-
currence of  uncontrolled viral replication and the failure 
of  immune surveillance. Therefore, since a preemptive 
reduction of  immunosuppression represents the mile 
stone for the treatment of  PVAN, virological and viro-
immunological monitoring are necessary and should be 
performed according to current recommendations. At 
moment, the reduction of  immunosuppression repre-
sents the first line of  intervention, however clinical con-
trolled trials are required to identify the best therapeutic 
strategies. A multidisciplinary approach is fundamental 
to optimize the clinical management of  renal transplant 
recipients and, despite of  the relevance of  consensus 
recommendations, these cannot substitute for clinical 
judgement and individualized care taking into account the 
different points of  view. 
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